Navigation Links
New MedPredict Report Assesses Current Outlook for Anticoagulants Market
Date:2/20/2009

Multi-Specialty Physician Panel Weighs in on Likely Positioning for Lilly/Daiichi's Prasugrel

SCOTTSDALE, Ariz., Feb. 20 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies developing anticoagulant therapies. This report is based on primary interviews conducted with cardiovascular experts from North America and Europe immediately following the American Society of Hematology (ASH) annual meeting.

"Anticoagulation therapy is being studied in a variety of settings, including elective and non-elective surgery, acute coronary syndrome, prevention and treatment of deep vein thrombosis/pulmonary embolism, secondary prevention of strokes in patients being treated for atrial fibrillation, and oncology," says Jeff Berk, MedPredict president. "Our Thought Leaders share their opinions on antithrombotics and antiplatelets driven by different patient populations and differing therapeutic goals."

The report addresses the following questions:

  • Which patient populations are most likely to be prescribed Effient (prasugrel), and how are physicians likely to balance efficacy versus bleeding risk? How does this vary by specialty?
  • Is daily oral anticoagulant therapy preferable to a monthly parenteral dose?
  • What do acute coronary syndrome treaters want that pharma is not currently providing?
  • How do different specialists view the strengths and weaknesses of the various anticoagulant therapies in development?

"Our panel reviews all of the key compounds in the pipeline and distills a massive amount of information down to the most critical insights drug developers should have for decision-making," according to Dr. Berk.

Companies mentioned in this report include: Astellas, AstraZeneca, Bayer-Schering, Bristol-Meyers Squibb, Daiichi Sankyo, GlaxoSmithKline, Lilly, Pfizer, Portola, Sanofi-Aventis, Schering-Plough, Takeda, The Medicines Company.

This report can be purchased by contacting MedPredict (www.medpredict.com).

About MedPredict

MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiovascular Meds May Be Beneficial in Alzheimers Disease, According to MedPredict Report
2. MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development
3. Virginia Tech Report Has National Importance
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
6. Haemacure Reports Third Quarter 2007 Results
7. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
8. Biotech Finishes on a High in August, Burrill Report Says
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine ... Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology: